Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

CASC 4.63 +0.07 (1.54%)
price chart
The Cascadian Therapeutics Inc. (CASC) Rating Decreased to Sell at The Zacks ...
Zacks Investment Research cut shares of Cascadian Therapeutics Inc. (NASDAQ:CASC) from a hold rating to a sell rating in a research note released on Thursday.
Zacks Investment Research Lowers Cascadian Therapeutics, Inc. (CASC) to Sell  Community Financial News
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Appoints Dr. Marc ...
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced the appointment of Marc L. Lesnick, Ph.D., as Senior Vice President, Regulatory Affairs and Quality where he will lead the development of global regulatory strategy and quality processes, ...
Cascadian Therapeutics, Inc. (CASC) Upgraded to Hold at Zacks Investment ...  Sports Perspectives
Cascadian Therapeutics, Inc. (CASC) Stock Rating Lowered by Zacks Investment ...
Cascadian Therapeutics, Inc. (NASDAQ:CASC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
Cascadian Therapeutics, Inc. (CASC) Downgraded by Zacks Investment Research ...  BBNS
Cowen Dives in on Cascadian Therapeutics Inc (USA) (CASC) Following HER2CLIMB ...
Cowen analyst Boris Peaker weighed in on Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) with a few insights after the company announced that following a recent meeting with the FDA and discussions with the Company's external Steering Committee, ...
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that its board of directors has approved a plan for a reverse split of the Company's common stock to increase its share price and reduce the number of authorized and outstanding shares.
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) Likely to Breakout
Investors should take note of the 14% jump in the share price of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) yesterday on a traded volume of 2.01 million shares.
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Receives ONT-380 ...
Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug ...
Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Cascadian Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare ...
20, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Julie Eastland, Chief Financial Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare ...
Cascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib ...
SEATTLE, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names ...